RxPG News : Prostate Cancer

Survey on PSA screening in young men

Mon, 11 Aug 2008 08:48:13 PST

A new analysis finds that one in five men in their 40s has had a prostate specific antigen (PSA) test within the previous year and that young black men are more likely than young white men to have undergone the test. The study, published in the September 15, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society, provides valuable information as experts discuss possible changes to prostate cancer screening recommendations.

New, noninvasive prostate cancer test beats PSA in detecting prostate cancer

Tue, 05 Feb 2008 22:25:00 PST

An experimental biomarker test developed by researchers at the University of Michigan more accurately detects prostate cancer than any other screening method currently in use, according to a study published in the February 1 issue of Cancer Research, a journal of the American Association for Cancer Research.

Statin use linked with decreased prostate cancer mortality rates; lower PSA levels

Tue, 22 May 2007 10:00:00 PST

ANAHEIM, Ca. (May 20, 2007) -- Urologists and researchers have postulated in recent years that statin medications could have an impact on the growth and progression of prostate cancer. Cholesterol is a primary building block for testosterone, which has in turn been linked with prostate tumor growth (less testosterone results in slower-growing tumors). In recent years, research has indicated a possible link between dietary fat intake and prostate cancer. Research presented today at the 102nd Annual Scientific Meeting of the American Urological Association explores the effect statin medications (which work to reduce low-density lipoprotein, or LDL, levels) may have on prostate-specific antigen, the incidence of prostate cancer, and mortality due to prostate cancer. A special session for members of the media was held on May 20 at 11:00 a.m. and moderated by AUA spokesman Anthony Y. Smith, M.D. of the University of New Mexico, Albuquerque.

New research supports early testing for prostate cancer

Sun, 20 May 2007 10:05:00 PST

Prostate cancer is the third-leading cause of cancer deaths among American men and is most treatable when caught in its earliest stages. Research presented today during the 102nd Annual Scientific Meeting of the American Urological Association in Anaheim, Ca. provided further evidence supporting regular prostate-cancer screening and offered new insights into disease progression and the hormonal treatment of recurrent disease. A special session for media highlighting this research was held on May 20 at 9:00 a.m. PDT and was moderated by AUA spokesman Christopher L. Amling, M.D.

Genetic marker linked to aggressive prostate cancer

Sun, 20 May 2007 04:00:00 PST

Northwestern University researchers have discovered that a recently identified genetic marker for prostate cancer is linked to a highly aggressive form of the disease.

Study identifies multiple genetic risk factors for prostate cancer

Sun, 01 Apr 2007 11:49:08 PST

A study led by researchers at the Keck School of Medicine of the University of Southern California (USC) and Harvard Medical School has identified seven genetic risk factorsâDNA sequences carried by some people but not othersâthat predict risk for prostate cancer. According to the study's findings, these risk factors are clustered in a single region of the human genome on chromosome 8 and powerfully predict a man's probability of developing prostate cancer. The paper will be published in the online edition of Nature Genetics on April 1.

Soy-rich Japanese diet decreases the risk of localized prostate cancer, increases the risk of advanced prostate cancer- Study reports

Tue, 27 Mar 2007 00:49:40 PST

The largest study examining the relationship between the traditional soy-rich Japanese diet and development of prostate cancer in Japanese men has come to a seemingly contradictory conclusion: intake of isoflavone chemicals, derived largely from soy foods, decreased the risk of localized prostate cancer but increased the risk of advanced prostate cancer.

Green tea and COX-2 inhibitors combine to slow growth of prostate cancer

Thu, 01 Mar 2007 05:34:47 PST

Drinking a nice warm cup of green tea has long been touted for its healthful benefits, both real and anecdotal. But now researchers have found that a component of green tea, combined with low doses of a COX-2 inhibitor, could slow the spread of human prostate cancer.

Prostate brachytherapy causes fewer side effects than surgery

Wed, 28 Feb 2007 10:13:20 PST

Men with prostate cancer have a slightly better long-term side effects profile with radiation seed implants than they do with surgery, according to a study released today in the International Journal for Radiation Oncology*Biology*Physics, the official journal of ASTRO.

Researcher identifies men who require second prostate biopsy

Thu, 22 Feb 2007 10:07:18 PST

A researcher in the Oregon Health & Science University Cancer Institute and Portland Veterans Affairs Medical Center has found a way to identify which men need a second prostate biopsy because they may be harboring life-threatening prostate cancer even though they were given a clean bill of health after their first biopsy. Mark Garzotto, M.D., has been invited to present his findings on Thursday, Feb. 22, at the Multidisciplinary Prostate Cancer Symposium in Orlando, Fla. He is the director of urologic oncology at the Portland Veterans Affairs Medical Center, assistant professor of surgery (urology) in the OHSU School of Medicine, and member of the OHSU Cancer Institute. Also involved in the research is Shane Rogosin, M.D., resident, in general internal medicine, and geriatrics, OHSU School of Medicine.

Prostate cancer less likely to spread when treated with higher dose of radiation

Fri, 24 Nov 2006 23:46:47 PST

New research suggests that men with prostate cancer who choose radiation therapy should seek treatment centers that will offer high-dose radiation. A new study from Fox Chase Cancer Center finds that higher doses of 74 to 82 Gray (Gy) greatly reduce the risk that the cancer will spread later--even 8-10 years after treatment. The results of the study were presented today at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology in Philadelphia.

Gene therapy study takes aim at prostate cancer

Tue, 26 Sep 2006 22:41:00 PST

Researchers at Baylor College of Medicine (BCM) are hoping a new gene therapy that takes a gene called RTVP-1 directly into the prostate tumor will prove effective in preventing recurrence of the disease. The first phase of the study is designed to test the safety of the treatment and determine the proper dosage of gene, said Dr. Dov Kadmon, professor of urology at BCM. It will be carried out in the department of urology at BCM as well as at Ben Taub General Hospital, The Methodist Hospital and Michael E. DeBakey Veterans Affairs Medical Center.

Pain associated with prostatic biopsy is related to the site biopsied

Fri, 15 Sep 2006 03:02:00 PST

Researchers at Mayo Clinic have evaluated the major sources of pain for some men during in-office prostate biopsy and an anesthetic method that can best lessen it. Findings will be presented in two abstracts Thursday at the annual meeting of the North Central Section of the American Urological Association in San Diego.

Admixture mapping reveals locus for prostate cancer risk

Tue, 22 Aug 2006 04:24:00 PST

Harvard Medical School researchers have identified a DNA segment on chromosome 8 that is a major risk factor for prostate cancer, especially in African American men. The paper appears in the August 21 electronic edition of the Proceedings of the National Academy of Sciences.

Diet modification and stress reduction may attenuate progression of prostate cancer

Tue, 15 Aug 2006 22:18:00 PST

Statistics say that one out of six American men will develop prostate cancer and more than a third of them will experience a recurrence after undergoing treatment, putting them at high risk to die of the disease.

Prostatic Irradiation Doesnt Lead To Any Appreciable Increase in Rectal Cancer Risk

Tue, 04 Jul 2006 00:12:00 PST

Men who receive radiation therapy for prostate cancer are not at any appreciable increased risk of developing rectal cancer compared to those not given radiation therapy, according to a new study published in the July 1, 2006, issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO, the American Society for Therapeutic Radiology and Oncology.

Pomegranate Juice Slows PSA Acceleration Rate

Sat, 01 Jul 2006 17:33:00 PST

Pomegranate juice packs a punch on prostate cancer that prolongs post-surgery PSA doubling time, drives down cancer cell proliferation and causes prostate cancer cells to die, according to a study published in the July 1 issue of Clinical Cancer Research. Researchers at the Jonsson Cancer Center at UCLA reported that patients with recurrent prostate cancer who drank pomegranate after surgery or radiation treatment saw their PSA blood content levels double after about 54 months. By comparison, PSA levels in the same patients prior to drinking the daily doses of eight-ounce pomegranate juice accelerated more quickly, doubling their PSA levels in only 15 months.

Pomegranate juice could kill cancer cells

Sat, 01 Jul 2006 14:57:00 PST

Drinking an eight ounce glass of pomegranate juice daily could slow the progress of prostate cancer, minimise cell damage and could also kill cancer cells, finds a new study. Researchers led by Allan Pantuck at the University of California, Los Angeles, studied 50 men who had undergone surgery or radiation treatment for prostate cancer - but had shown signs that the disease was rapidly returning.

Early estrogen exposure leads to later prostate cancer risk

Thu, 01 Jun 2006 12:53:00 PST

A study in the June 1 issue of Cancer Research presents the first evidence that exposure to low doses of environmental estrogens during development of the prostate gland in the male fetus may result in a predisposition to prostate cancer later in life.

JHDM2A enzyme induced H3K9 demethylation offers new look at male hormone regulation

Sun, 07 May 2006 15:15:00 PST

For the second time in less than a year, University of North Carolina at Chapel Hill scientists have purified a novel protein and have shown it can alter gene activity by reversing a molecular modification previously thought permanent.

What is the appropriate age to stop prostate cancer screening?

Wed, 03 May 2006 00:46:00 PST

Screening for prostate cancer in older men has been problematic. While this form of cancer can be fatal, it often progresses so slowly that men are more likely to die from some other disease. Aggressive treatments such as radical prostatectomy or radiation therapy may eradicate the cancer but have negative effects on quality of life. More conservative treatments may preserve quality of life, but may not be appropriate for those cases where the disease is progressing more quickly. In the face of these uncertainties, what is the appropriate age to stop screening?

High cholesterol may contribute to prostate cancer

Wed, 12 Apr 2006 18:11:00 PST

High cholesterol may contribute to the development of prostate cancer although further studies are needed to confirm the results, say scientists.

Human infections documented with a native rodent retrovirus

Fri, 31 Mar 2006 12:51:00 PST

Howard Hughes Medical Institute researchers and their colleagues have discovered a new retrovirus in humans that is closely related to a cancer-causing virus found in mice. Their findings describe the first documented cases of human infection with a retrovirus that is native to rodents.

Alterations in DNA methylation is a better indicator of prostate cancer

Tue, 28 Mar 2006 21:16:00 PST

Researchers at Mayo Clinic have narrowed the search for effective prostate cancer biomarkers (genetic variations that point to a specific disease or condition), identifying changes in the expression of genes of the whole genome closely correlated to prostate cancer development and progression. They also showed that DNA hypermethylation (DNA modification without changing sequence) plays a significant role in these processes. Results of their study were published in the Feb. 15 issue of Clinical Cancer Research.

Prostate treatment decisions based on perception more than fact

Mon, 27 Mar 2006 16:23:00 PST

Men with prostate cancer generally make treatment decisions based on differences in the information they receive rather than their own preferences, according to a new review. Published in the May 1, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the review of studies in prostate cancer decision making suggests that a lack of medical evidence and consistent, comprehensive messages about therapeutic options compel men to turn to a wide variety of popular and biased sources, which influence their decision. This approach often results in treatments that do not generally reflect patients' goals.

Older men with early prostate cancer survived longer with treatment vs. observation

Sun, 26 Feb 2006 17:31:00 PST

A new study shows older men with early stage prostate cancer survive longer if they are treated versus not being treated in favor of the "watchful waiting" approach advocated by many physicians for older men with other health problems. In addition, the study revealed a survival benefit for men treated with radiation therapy making it the first study to demonstrate a survival advantage in an older population.

Cabbage, cauliflower and turmeric please!

Tue, 17 Jan 2006 01:33:00 PST

Rutgers researchers have found that the curry spice turmeric holds real potential for the treatment and prevention of prostate cancer, particularly when combined with certain vegetables

Speed of PSA increase is a better prognostic marker

Sat, 12 Nov 2005 20:03:00 PST

In the largest study of its kind to date, Mayo Clinic researchers report that prostate specific antigen (PSA) kinetics, both velocity and doubling time, can be used to predict disease progression and likelihood of death after radical prostatectomy surgery, suggesting that this could be used to guide treatment decisions.

Pomegranate Juice to Combat Prostate Cancer

Tue, 27 Sep 2005 21:12:00 PST

With more than 230,000 new cases of prostate cancer expected to be diagnosed this year alone in the U.S. and the outlook poor for patients with metastatic disease, researchers are looking for new strategies to combat the disease. Earlier research at Wisconsin and elsewhere has shown that the pomegranate, a fruit native to the Middle East, is rich in anti-oxidant and anti-inflammatory activity and is effective against tumors in mouse skin. In fact, pomegranate juice has higher anti-oxidant activity than do red wine and green tea, both of which appear promising as anti-cancer agents.

EphB2 mutation linked with prostate cancer risk in african-americans

Wed, 21 Sep 2005 19:10:00 PST

Researchers have identified a gene mutation that may increase the risk of prostate cancer up to three times in African-American men with a family history of the disease.

Committee Supports New Indication for EGFR Inhibitor Erlotinib

Wed, 14 Sep 2005 21:32:00 PST

OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Genentech, Inc. (NYSE: DNA) announced today that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 to 3 in favor of recommending approval of Tarceva® (erlotinib) in combination with gemcitabine for the treatment of advanced pancreatic cancer in patients who have not received previous chemotherapy. Tarceva is the first drug in a Phase III trial to have shown a significant improvement in overall survival when added to gemcitabine chemotherapy in first-line pancreatic cancer. Tarceva is an oral tablet currently approved for use in non-small cell lung cancer (NSCLC) for patients whose disease has progressed after one or more courses of chemotherapy. The FDA will now review the ODAC recommendation and a decision on Tarceva approval is anticipated by November 2, 2005.

PSA remains the best indicator of cancer recurrence after surgery

Tue, 13 Sep 2005 04:32:00 PST

Despite recent claims by some urologists that measuring the blood protein prostate-specific antigen (PSA) may not be effective in predicting risk of prostate cancer, a Johns Hopkins study of more than 2,000 men confirms that PSA remains the best measure of the likelihood of cancer recurrence after surgery.

Expensive robot-assisted prostate surgery has possible benefits

Mon, 29 Aug 2005 22:31:00 PST

Although minimally invasive prostate removal aided by a robot can lead to less blood loss, shorter hospital stays and fewer complications, there is no evidence that the procedure improves cure rates, according to a new technology assessment.

Predicting prostate cancer outcome with activated Stat5 protein

Mon, 15 Aug 2005 17:47:00 PST

Researchers from Lombardi Comprehensive Cancer Center at Georgetown University found that testing for an activated Stat5 protein in prostate tumor tissue effectively predicts which men have a form of prostate cancer that may become more aggressive and life threatening.

PSA velocity shown to be associated with tumor stage

Fri, 29 Jul 2005 00:47:00 PST

Men who have a higher rate of increase in their PSA value in the year prior to their prostate cancer diagnosis have a significantly higher risk of death following radiation therapy, according to a study in this issue of JAMA.

Predicting risk of death after radical prostatectomy

Thu, 28 Jul 2005 23:17:00 PST

Clinical factors including the time to biochemical recurrence following surgery can help predict the risk of prostate cancer death for patients following a radical prostatectomy, according to a study in the July 27 issue of JAMA

Normal life after radiation for prostate cancer

Sat, 16 Jul 2005 00:00:00 PST

Men receiving radiation therapy to combat early-stage prostate cancer are still able to achieve an erection and face a low rate of incontinence one year following treatment, according to a new study published in the July 15, 2005 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO, the American Society for Therapeutic Radiology and Oncology.

Continuum of prostate cancer risk at all values of PSA - Study

Fri, 08 Jul 2005 13:29:00 PST

A new study indicates there is no specific PSA value that has both high sensitivity and high specificity for monitoring healthy men for prostate cancer, but rather there is a continuum of prostate cancer risk at all values of PSA, according to a study in the July 6 issue of JAMA.

Hyperthermia Therapy as a New Approach to Treat Prostate Cancer

Tue, 21 Jun 2005 21:41:00 PST

BSD Medical Corp. (AMEX:BSM) has announced the conclusion of a highly successful conference of the 2005 annual European Society of Hyperthermic Oncology (ESHO) held in Graz, Austria, in which major breakthroughs in therapies tied to BSD's cancer treatment equipment were reported. Of the 74 presentations made at the conference, some of the highlights are being reported in several follow-up press releases.

Prostate-specific Membrane Antigen Emerging as an Important Therapeutic Target to Deal with Prostate Cancer

Tue, 21 Jun 2005 10:50:00 PST

The license provides PDC with rights to utilize the ADC technology to link cell-killing drug payloads to PDC's fully human monoclonal antibodies that target prostate-specific membrane antigen (PSMA), which is highly expressed on both primary and metastatic prostate cancer cells.

Delaying radiation for prostate cancer does not affect outcome

Tue, 14 Jun 2005 06:09:00 PST

For men diagnosed with prostate cancer, there is no risk of recurrence if external beam radiation therapy (EBRT) is delayed by several months. A study published in the July 15, 2005 issue of CANCER, a peer-reviewed journal of the American Cancer Society, finds delays of EBRT had no harmful impact on clinical outcome or biochemical marker levels in low-, intermediate- and high-risk patients.

Groundbreaking discovery of the ETS-Related Gene (ERG)

Sun, 12 Jun 2005 06:08:00 PST

Researchers led by Dr. Shiv Srivastava from the Center for Prostate Disease Research (CPDR), Uniformed Services University of the Health Sciences (USU), report the groundbreaking discovery of the ETS-Related Gene (ERG) as one of the frequent proto-oncogene overexpressions in prostate cancer cells. This discovery provides a very promising addition to a select group of genes, whose expression is frequently altered in prostate cancer cells and could provide novel molecular targets for diagnosis, prognosis or therapy of prostate cancer in the future.

Pros and Cons of All Possible Treatments of Prostate Cancer

Mon, 30 May 2005 21:18:00 PST

Prostate cancer continues to be a leading priority among medical researchers. For this reason, a special panel briefing dedicated to prostate cancer treatments and outcomes will be held during the 100th Annual Scientific Meeting of the American Urological Association (AUA) on May 25, 2005 in the Henry B. Gonzalez Convention Center in San Antonio. J. Brantley Thrasher, M.D., a spokesperson for the AUA and chair of urologic surgery at the University of Kansas Medical Center, will moderate the briefing, which will feature research on best treatments for high-grade prostate cancer.

QUADRAMET® with Docetaxel Demonstrate Good Palliative Effect in Prostate Cancer

Tue, 17 May 2005 09:07:00 PST

Cytogen Corporation (Nasdaq: CYTO - News), a product-driven biopharmaceutical company, today announced the publication of data from a phase II study of QUADRAMET® (samarium Sm-153 lexidronam injection), the Company's flagship product, in combination with docetaxel (Taxotere®, Aventis Pharmaceuticals, a member of the sanofi- aventis Group) for the treatment of patients with hormone refractory prostate cancer.

Toremifene May Reduce Cancer Risk in Men with Precancerous Prostate Cells

Tue, 17 May 2005 01:54:00 PST

In a multicenter phase IIb study, the hormone drug toremifene (Acopodene) reduced the risk of prostate cancer development by nearly half in men with prostatic intraepithelial neoplasia (PIN), a precancerous condition that can progress to prostate cancer.

New Advances in Prostate Cancer Treatment

Sun, 15 May 2005 02:23:00 PST

A Novel mTOR Inhibitor in Phase 2 as a Single Agent for Refractory Prostate cancer

Wed, 04 May 2005 22:15:00 PST

ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced initiation of enrollment of patients with prostate cancer who have become refractory to standard hormone therapy in a multi-center Phase 2 clinical trial of its novel mTOR inhibitor, AP23573, as a single agent.

Satraplatin for its Use in Second-Line Treatment for Hormone Refractory Prostate Cancer Continues in Phase 3

Wed, 20 Apr 2005 09:30:00 PST

Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced that its co-development partner for satraplatin, GPC Biotech AG (Nasdaq: GPCB) (Frankfurt Stock Exchange: GPC), disclosed that the independent Data Monitoring Board (DMB) for the satraplatin Phase 3 SPARC registrational trial in second-line hormone refractory prostate cancer held a meeting on April 18, 2005 to review safety data from the ongoing study. The DMB reviewed the safety data from the first 262 patients who were randomized in the trial and had completed at least one cycle of treatment. After reviewing the data, the DMB reported that the design and conduct of the trial remain sound and recommended that the trial continue as planned.

Does Screening for Prostate Cancer with PSA Actually Save Men's Lives?

Sun, 10 Apr 2005 09:08:00 PST

Screening for prostate cancer with a PSA (prostate specific antigen) blood test, though routinely performed today in men middle-aged and older, remains a source of controversy. Questions continue about the test's overall effectiveness and its ability to actually save men's lives.

Advanced Prostate Cancer may be Curable

Sun, 03 Apr 2005 11:25:00 PST

New findings from Mayo Clinic indicate that cT3 prostate cancer, a disease in which the cancer has spread locally from inside the prostate to immediately outside it, is operable and has 15-year cancer survival rates of almost 80 percent.

NICE Supports High Intensity Focused Ultrasound (HIFU) for the Treatment of Localized Prostate Cancer

Sun, 03 Apr 2005 09:56:00 PST

EDAP TMS S.A. (Nasdaq: EDAP - News), today welcomed the publication of the U.K. National Institute for Clinical Excellence (NICE) recent guidelines supporting the use of High Intensity Focused Ultrasound (HIFU) for the treatment of localized prostate cancer.

Surgery, Not Radiotherapy Offers Better Survival Advantage for Stage 3 Prostate Cancer

Sun, 03 Apr 2005 09:39:00 PST

Socio-Cultural factors play a significant role in Prostate Cancer Treatment Decisions

Mon, 28 Mar 2005 21:05:00 PST

Researchers say social and cultural factors play a significant role in patients' prostate cancer treatment decisions.

New Prostate Cancer Suppressor Gene Found

Wed, 23 Mar 2005 00:28:00 PST

A gene named ATBF1 may contribute to the development of prostate cancer through acquired mutations and/or loss of expression, according to research at Emory University School of Medicine and its Winship Cancer Institute.

PLCO Trial Reports Baseline Data for Prostate Cancer Screening

Fri, 18 Mar 2005 23:18:00 PST

The prostate component of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Trial is designed to determine the impact of annual screening with prostate-specific antigen (PSA) testing and digital rectal exam on mortality from prostate cancer by comparing one group of men who receive screening with a control group of men undergoing routine medical care. In a new study, Gerald L. Andriole, M.D., of the Washington University School of Medicine in St. Louis, and colleagues report findings from the initial round of screening. The final results of the trial are still several years away.

Earlier use of Prostate Cancer Vaccines is More Effective

Fri, 18 Mar 2005 22:18:00 PST

Timing is everything when it comes to killing prostate cancer cells with specially tailored vaccines, say scientists testing the drugs in mice at the Johns Hopkins Kimmel Cancer Center.

Cholesterol Helps Prostate Tumors Survive and Grow

Fri, 18 Mar 2005 15:24:00 PST

Researchers at Children's Hospital Boston have demonstrated that high blood cholesterol levels accelerate the growth of prostate tumors, showing that cholesterol helps prostate tumors survive and grow at the molecular level by altering chemical signaling patterns within tumor cells.

An Adoptive Transfer Gene Therapy Technique to Deal with Metastatic Prostate Cancer

Sun, 13 Mar 2005 08:52:00 PST

The findings of the Northwestern study provide a proof of principle that an adoptive transfer of tumor-reactive TGF-beta-insensitive CD8+ T cells may warrant consideration for the treatment of advanced tumors, Lee said.

KLF6 variant gene may increase risk of Prostate Cancer by 50%

Thu, 17 Feb 2005 21:35:00 PST

Prostate cancer is among the most prevalent cancers worldwide and is the second leading cause of male cancer-related death in the United States. Incidence is expected to double among men over age 65 in the next 25 years, according to the authors. "Our findings highlight a completely novel and previously unexplored pathway for the development of prostate cancer," said Dr. Martignetti. "Ultimately we plan to investigate the potential of this gene as a diagnostic tool, an indicator of a patients risk for prostate cancer, and as a potential target for new treatments."

Oral Phenoxodiol Gets Fast Track Designation for its use in Prostate Cancer

Thu, 27 Jan 2005 16:52:00 PST

Marshall Edwards, Inc.,today announced that the U.S. Food and Drug Administration (FDA) has granted the investigational anti-cancer drug, phenoxodiol, fast track status for its intended use in patients with hormone- refractory prostate cancer (HRPC).

Innovative planning techniques to help men with prostate cancer avoid erectile dysfunction after radiation treatment.

Fri, 07 Jan 2005 00:59:00 PST

Researchers at the University of Michigan Comprehensive Cancer Center are using innovative planning techniques to help men with prostate cancer avoid erectile dysfunction after radiation treatment.

Combining Hormones with External, Internal Radiation Helps High Risk Prostate Cancer Patients

Thu, 30 Dec 2004 17:35:00 PST

Prostate cancer patients with high risk cancers who are treated with both internal and external radiation and hormone treatment have a better chance of beating the disease than patients treated with radiation alone, according to a new study published in the January 1, 2005, issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO, the American Society for Therapeutic Radiology and Oncology.

Alternative immunotherapy for prostate cancer bone lesions

Thu, 16 Dec 2004 17:57:00 PST

Prostate cancer (PC) is the most commonly diagnosed malignancy and the second leading cause of death in American men. PC usually moves into the bone and the symptoms are treated by suppression of the production of male hormones known as androgens. However within 12-18 months of beginning this therapy, the disease usually becomes androgen-independent and no further effective therapies currently exist.